SKP2 and cancer: Lymphocyte-specific protein tyrosine kinase (LCK) phosphorylates Tyrosine-342 of FOXP3 and upregulates its expression resulting in decreased Matrix metalloproteinase 9 (MMP9), S-phase kinase-associated protein 2 (SKP2), and Vascular endothelial growth factor A (VEGF-A) levels in cancer cells (90).